Rep. Robert Bresnahan, Jr. Buys DexCom, Inc. (NASDAQ:DXCM) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in DexCom stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

DexCom Stock Performance

NASDAQ DXCM opened at $67.74 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $141.99. The company has a fifty day moving average of $82.32 and a 200-day moving average of $77.07. The company has a market capitalization of $26.47 billion, a P/E ratio of 47.37, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on DXCM shares. Morgan Stanley lifted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Canaccord Genuity Group boosted their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Cfra Research upgraded DexCom to a “hold” rating in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Fire Capital Management LLC purchased a new position in shares of DexCom in the 4th quarter valued at approximately $364,000. California State Teachers Retirement System raised its holdings in DexCom by 0.6% in the fourth quarter. California State Teachers Retirement System now owns 635,596 shares of the medical device company’s stock worth $49,430,000 after purchasing an additional 3,996 shares in the last quarter. PKO Investment Management Joint Stock Co purchased a new position in DexCom during the fourth quarter valued at $3,733,000. Mattson Financial Services LLC boosted its holdings in shares of DexCom by 20.4% during the 4th quarter. Mattson Financial Services LLC now owns 21,119 shares of the medical device company’s stock valued at $1,642,000 after buying an additional 3,584 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of DexCom in the 4th quarter worth about $41,295,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 in the last three months. 0.30% of the stock is owned by corporate insiders.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.